Terns Pharmaceuticals, Inc.

Equities

TERN

US8808811074

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:24:22 23/05/2024 pm IST			5-day change	1st Jan Change
5.82 ^USD	-1.85%		-5.05%	-10.17%

13/05	Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
08/05	Terns Pharmaceuticals, Inc. Announces Executive Changes	CI

Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022

March 28, 2023 at 01:44 am IST

Terns Pharmaceuticals, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 15.82 million compared to USD 14.25 million a year ago. Basic loss per share from continuing operations was USD 0.29 compared to USD 0.56 a year ago. Diluted loss per share from continuing operations was USD 0.29 compared to USD 0.56 a year ago.

For the full year, the company reported net loss was USD 60.35 million compared to USD 50.16 million a year ago. Basic loss per share from continuing operations was USD 1.67 compared to USD 2.21 a year ago. Diluted loss per share from continuing operations was USD 1.67 compared to USD 2.21 a year ago.

Latest news about Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Terns Pharmaceuticals, Inc. Announces Executive Changes	09/05	CI
Terns Pharmaceuticals, Inc. Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor Tern-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation	30/04	CI
Terns Pharmaceuticals, Inc. Appoints Melita Sun Jung as Chief Business Officer	11/04	CI
UBS Trims Terns Pharmaceuticals Price Target to $18 From $19, Maintains Buy Rating	27/03	MT
North American Morning Briefing : Stocks Struggle After New Records	22/03	DJ
JMP Securities Cuts Terns Pharmaceuticals Price Target to $15 From $17, Maintains Market Outperform Rating	18/03	MT
BMO Capital Adjusts Price Target on Terns Pharmaceuticals to $19 From $18, Maintains Outperform Rating	15/03	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03	CI
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03	CI
Terns Pharmaceuticals Gets Orphan Drug Label for Chronic Myeloid Leukemia Treatment Candidate	12/03	MT
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Chief Executive Officer	07/02	CI
Terns Pharmaceuticals, Inc. Appoints Amy Burroughs as Member of Board of Directors	07/02	CI
Jefferies Adjusts Terns Pharmaceuticals Price Target to $22 From $18, Maintains Buy Rating	18/01	MT
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $5.50 From $8, Maintains Neutral Rating	10/01	MT
Mizuho Adjusts Price Target on Terns Pharmaceuticals to $10 From $17, Maintains Buy Rating	27/11	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Terns Pharmaceuticals, Inc. Announces First Participant Dosed in Phase 1 Clinical Trial of TERN-601 Oral GLP-1 Receptor Agonist for Treatment of Obesity	03/11	CI
Terns Pharmaceuticals, Inc.(NasdaqGS:TERN) added to S&P Global BMI Index	18/23/18	CI
HC Wainwright Adjusts Price Target on Terns Pharmaceuticals to $8 From $11, Keeps Neutral Rating	10/23/10	MT
Mizuho Ups Price Target on Terns Pharmaceuticals to $17 From $16, Keeps Buy Rating	09/23/09	MT
Terns Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Terns Pharmaceuticals, Inc. Achieves Primary Endpoint and All Secondary Endpoints in Phase 2a DUET Trial of THR-ß Agonist TERN-501 in NASH	09/23/09	CI
Terns Pharmaceuticals Chief Executive Senthil Sundaram Resigns Due to Health Reasons	04/23/04	MT
Terns Pharmaceuticals, Inc. Announces Leadership Transition	04/23/04	CI

Chart Terns Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.

Sector

Biotechnology & Medical Research

Calendar

10:30pm - UBS Obesity Therapeutics Day - Fireside Chat

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.93 USD

Average target price

14.21 USD

Spread / Average Target

+139.70%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TERNS PHARMACEUTICALS, INC.	-10.17%	38Cr
MODERNA, INC.	+60.65%	6.26TCr
IQVIA HOLDINGS INC.	-3.24%	4.12TCr
LONZA GROUP AG	+44.70%	4.03TCr
CELLTRION, INC.	-8.29%	2.79TCr
ICON PUBLIC LIMITED COMPANY	+13.42%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.07%	1.91TCr
BIO-TECHNE CORPORATION	+4.52%	1.31TCr
UNITED THERAPEUTICS CORPORATION	+24.83%	1.23TCr
MEDPACE HOLDINGS, INC.	+27.52%	1.21TCr

Other Biotechnology & Medical Research